Background
Methods
Subjects
AATD + AUGa
| AATD + AUGb
| TD PFTnormc
| non-AATD COPDd
| Healthye
| |
---|---|---|---|---|---|
Lung health classification | COPD | COPD | Normal | COPD | Normal |
Genotype | PiZZ | PiZZ (PiSZ = 1) | PiZZ | PiMM | PiMM (PiMZ = 1) |
Number of subjects (m,f) | 6 (3,3) | 6 (2,4) | 4 (1,3) | 7 (4,3) | 5 (3,2) |
Age (years) | 56 ± 4 | 63 ± 5 | 55 ± 5 | 64 ± 2 | 56 ± 1 |
Height (cm) | 177 ± 3 | 170 ± 4 | 172 ± 5 | 167 ± 4 | 172 ± 5 |
Weight (kg) | 80 ± 10 | 83 ± 13 | 77 ± 9 | 82 ± 8 | 86 ± 10 |
DXA body fat (%) | 32 ± 4 | 37 ± 3 | 33 ± 7 | 30 ± 4 | 32 ± 5 |
Lean body mass (kg) | 54 ± 6 | 52 ± 8 | 51 ± 7 | 57 ± 5 | 58 ± 7 |
Body mass Index (kg/m2) | 25 ± 2 | 28 ± 3 | 26 ± 3 | 29 ± 2 | 29 ± 2 |
Fat-free index (kg/m2) | 17 ± 1 | 18 ± 2 | 17 ± 2 | 20 ± 1 | 19 ± 1 |
Lean body mass (DXA) (kg) | 49 ± 7 | 51 ± 7 | 48 ± 7 | 53 ± 5 | 54 ± 6 |
Thigh mass (DXA) (kg) | 16 ± 2 | 13 ± 2 | 16 ± 2 | 15 ± 1 | 16 ± 2 |
Medication
| |||||
No prescribed meds | 0% | 0% | 100% | 14% | 60% |
AAT Augmentation Therapy | 100% | 0% | 0% | 0% | 0% |
Bronchodilator | 100% | 100% | 0% | 86% | 0% |
Inhaled corticosteriods | 83% | 83% | 0% | 71% | 0% |
Oxygen | 33% | 0% | 0% | 29% | 0% |
Diuretics | 0% | 17% | 0% | 14% | 0% |
Anti-inflammatory | 0% | 0% | 0% | 0% | 0% |
Anti-depressive | 0% | 17% | 0% | 29% | 0% |
β-blockers | 33% | 33% | 0% | 29% | 40% |
Serum liver function tests
| |||||
Total Bilirubin (mg/dL) | 0.48 ± 0.06 | 0.50 ± 0.12 | 0.45 ± 0.09 | 0.37 ± 0.05 | 0.51 ± 0.12 |
Albumin (g/dL) | 3.80 ± 0.17 | 3.45 ± 0.15 | 3.80 ± 0.12 | 3.77 ± 0.11 | 3.82 ± 0.06 |
Alanine Aminotransferase (U/L) | 42.3 ± 15.2 | 28.5 ± 3.4 | 41.0 ± 12.7 | 23.4 ± 5.3 | 30.6 ± 2.9 |
Serum AAT level (mg/dl) | 96 ± 22b,c
| <20 ± 0a,d,e
| <20 ± 0a,d,e
| 113 ± 11b,c
| 109 ± 12b,c
|
AATD + AUGa
| AATD-AUGb
| AATD PFTnormc
| non-AATD COPDd
| Healthye
| |
---|---|---|---|---|---|
FVC (liters) | 3.85 ± 0.42 | 2.88 ± 0.16c
| 4.27 ± 0.64e
| 2.80 ± 0.32c,e
| 3.96 ± 0.57d
|
FVC (% pred) | 88 ± 6c
| 79 ± 5c
| 109 ± 6e
| 77 ± 8c,e
| 95 ± 6d
|
FEV1 (liters) | 1.23 ± 0.25c,e
| 1.35 ± 0.22c,e
| 3.22 ± 0.47e
| 1.49 ± 0.11c,e
| 3.07 ± 0.35d
|
FEV1 (% pred) | 35 ± 5c,e
| 47 ± 7c,e
| 107 ± 4e
| 54 ± 7c,e
| 93 ± 4d
|
FEV1/FVC | 31 ± 3c,d,e
| 47 ± 7c,e
| 76 ± 7c,e
| 56 ± 4c,e
| 79 ± 2d
|
FEV1/FVC (% pred) | 40 ± 4c,d,e
| 61 ± 10c,e
| 97 ± 2e
| 71 ± 6c,e
| 99 ± 3d
|
Bike (two-legs) exercise
| |||||
Watts | 62 ± 6c,e
| 46 ± 11c,e
| 176 ± 47d,e
| 70 ± 11c,e
| 126 ± 17d
|
VO2peak (L/min) | 1.02 ± 0.11c,e
| 0.69 ± 0.13c,e
| 2.07 ± 0.51d
| 1.16 ± 0.12c,e
| 1.71 ± 0.25d
|
VO2peak (ml/kg/min) | 12.6 ± 0.5c
| 9.5 ± 1.1c,e
| 26.9 ± 5.6d,e
| 14.9 ± 1.7c
| 20.3 ± 3.3 |
Knee extensor (single-leg) exercise
| |||||
Watts | 25 ± 3c
| 21 ± 7c
| 59 ± 23d,e
| 21 ± 3c
| 26 ± 1 |
Smoking history
| |||||
Never | 17% | 0% | 25% | 0% | 0% |
Ex-smoker | 83% | 100% | 75% | 43% | 100% |
Current | 0% | 0% | 0% | 57% | 0% |